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Genetic depletion of Polo-like kinase 1
leads to embryonic lethality due to
mitotic aberrancies
Paulina Wachowicz1) 2), Gonzalo Fernández-Miranda1) 3), Carlos Marugán1),
Beatriz Escobar 1) 4) and Guillermo de Cárcer 1)*
Polo-like kinase 1 (PLK1) is a serine/threonine kinase that
plays multiple and essential roles during the cell division
cycle. Its inhibition in cultured cells leads to severe mitotic ab-
errancies and cell death. Whereas previous reports suggested
that Plk1 depletion inmice leads to a non-mitotic arrest in early
embryos, we show here that the bi-allelic Plk1 depletion in
mice certainly results in embryonic lethality due to extensive
mitotic aberrations at the morula stage, including multi- and
mono-polar spindles, impaired chromosome segregation and
cytokinesis failure. In addition, the conditional depletion of
Plk1 during mid-gestation leads also to severe mitotic aber-
rancies. Our data also confirms that Plk1 is completely dis-
pensable for mitotic entry in vivo. On the other hand, Plk1
haploinsufficient mice are viable, and Plk1-heterozygous fi-
broblasts do not harbor any cell cycle alterations. Plk1 is
overexpressed in many human tumors, suggesting a thera-
peutic benefit of inhibiting Plk1, and specific small-molecule
inhibitors for this kinase are now being evaluated in clinical tri-
als. Therefore, the different Plk1 mouse models here pre-
sented are a valuable tool to reexamine the relevance of the
mitotic kinase Plk1 during mammalian development and ani-
mal physiology.
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spindle dynamics.
Introduction
Polo-like kinase 1 (Plk1) was discovered, among many other
cell cycle genes, in the 1980s from genetic screens performed
in yeast and Drosophila [1–3]. Subsequently, Plk1 was re-
vealed as a kinase very well conserved through evolution, from
yeast (Cdc5 in Saccharomyces Cerevisae) to insects (Polo in D.
melanogaster), amphibians (Plx1 in Xenopus laevis) and mam-
mals (Plk1 in Homo sapiens) [4–9]. In the following years, the
Polo-like kinase family expanded, and four members were
added (Plk1, Plk3, Plk4 and very recently Plk5) [10–12]
Polo-like kinase 1 is a master regulator of cell division, control-
ling several important processes throughout the cell cycle, such
as centrosome maturation [13], Golgi breakdown [14–17], spindle
assembly [18–21], chromosome segregation [20,22,23] and cyto-
kinesis [24–30]. All these processes are regulated by Plk1 upon
phosphorylation of many different substrates [31]. Plk1 is differ-
entially localized in the cell depending on the cell cycle phase
[10]. During interphase, Plk1 is located at the cytoplasm and cen-
trosomes. At the mitotic onset, when the nuclear envelope breaks
down, Plk1 is highly concentrated at the migrating centrosomes
and shuttles to the kinetochores of the condensed chromo-
somes. During chromosome separation at anaphase, Plk1 deco-
rates the mitotic mid-zone, hence becoming concentrated at the
mid-body where the two daughter cells will be separated.
Polo-like kinase 1 has a canonical kinase domain at the N -
terminus. The regulatory domain, so-called the “polo-box do-
main” (PBD), is located at the C -terminus, and it confers the dis-
tinctiveness of the Polo-like kinase family [12,32,33]. The PBD is
a unique structure that allows the recognition of proteins by a
“pincer-like” 3D structure [34–36]. The mechanism by which
Plk1 binds to its substrates is mainly based on the recognition
of residues previously phosphorylated by other kinases [35,37].
Once Plk1 and the substrate are bound together, Plk1 can phos-
phorylate the substrate at neighboring residues. The recognition
site is mostly based on the consensus sequence Ser-[pSer/
pThr]-[Pro/X] [35]. Although this “phospho-priming” mecha-
nism is the most common way for Plk1 to find substrates,
there are also formal demonstrations that the Plk1 can bind
substrates regardless of their phosphorylation status [36,38].
Polo-like kinase 1 inactivation in somatic cells, either by
means of small-interference RNA or by chemical inhibition,
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leads to spindle aberrations and problems in chromosome
segregation and eventually to cell death due to a prolonged
mitotic arrest [39–41]. In addition, Plk1 genetic depletion during
animal development also promotes similar mitotic phenotypes
and consequently animal death. Mutant alleles of polo, the
Drosophila orthologue, leads to monopolar spindles in larval
neuroblasts [2], and a hypomorphic polo allele shows cytokinesis
failure in spermatocytes [42,43]. Similarly, depletion of the Plk1
yeast orthologues (Cdc5 in budding yeast, or plo1 in fision yeast)
leads to proliferation arrest due to division alterations [44].
In mammals, Plk1 is expressed mainly in proliferating tis-
sues [45,46]. In addition, this kinase is frequently found
overexpressed in many tumors, and this feature often corre-
lates with poor prognosis [47,48]. Consequently, Plk1 is cur-
rently considered a bona fide cancer therapeutic target. There is
a growing collection of small compounds that are able to inhibit
the kinase activity of Plk1 with high specificity. Several of these
inhibitors are currently tested in chemotherapy clinical trials for
different cancer types [49–52]. Therefore, any data resulting from
Plk1 depletion in a mammalian model are of high value in the
evaluation of Plk1 kinase as an anticancer therapeutic target.
In recent years, two mouse strains with genetically altered ex-
pression of Plk1 were reported. In 2008, Junjie Chen and col-
leagues described that embryos homozygous for a Plk1 gene-
trap allele did not show any mitotic alterations. Surprisingly, cells
appear to be arrested during interphase [53]. The other mouse
model, reported in 2011 [54], is an inducible knock-down of Plk1
by inserting a short-hairpin RNA (shRNA) in the murine Rosa26 lo-
cus. This depletion strategy is conditional, allowing depletion in
the adult animal. However, because depletion is driven by shRNA,
it is difficult to evaluate the effects of full Plk1 depletion in this
model, and embryonic development was not studied.
To clarify the effects of Plk1 depletion during embryonic devel-
opment, we have generated a gene-trap allele, targeting intron 2
of themouse Plk1 locus. Our data confirms that Plk1 is an essential
gene in mammals and Plk1-null mice die at the morula stage of
embryo development due to severe mitotic aberrancies. Interest-
ingly, Plk1 haploinsufficiency is fully compatible with animal life
and Plk1(+/) animals develop normally, as shown in previous re-
ports [53]. We have also generated a conditional knock-out mice,
to allow Plk1 depletion after embryonic mid-gestation. Conditional
depletion of Plk1 at embryonic day E12.5 also leads to mitotic
aberrations. Concomitantly, mouse embryonic fibroblasts (MEFs)
derived from the Plk1(+/) animals do proliferate with similar ki-
netics as their wild-type littermates and do not show any alteration
in the cell cycle, whereas MEFs fully depleted of Plk1 show all the
classical mitotic alterations already described. Thus, here we show
that Plk1 is essential for the mammalian embryonic development,
and its depletion leads to mitotic alterations and lethality at differ-
ent stages during mammalian development.
Results
Plk1-deficient embryos show high levels of mitotic
aberrancies
We have generated a Plk1(+/) mutant mouse by using homol-
ogous recombination in Embryonic Stem (ES) cells with a
specific insertion of a β-geo cassette into intron 2 of the
mouse Plk1 locus (Fig. 1A). No viable Plk1(/) mice were born
from crosses between Plk1(+/) heterozygous mice, and ho-
mozygous embryos were not found at any stage after implan-
tation (E8.5) (Fig. 1B). We then tested the viability of the Plk1
null embryos at day E1.5 by isolating them immediately after
fertilization and tracking their development in an in vitro
culture. As depicted in Fig. 1C, both Plk1(+/+) and Plk1(+/)
embryos develop well in vitro during 4 days, reaching a morula
like stage. The insertion of the β-geo cassette was verified by
PCR (Fig. 1D), and the Plk1 expression during these initial
stages was monitored by β-galactosidase staining activity
(Fig. 1E), as well as immunofluorescence with Plk1-specific an-
tibodies (Fig. 2B and C). Plk1(/) mutant embryos arrest at
the morula stage by E3.5 and do not progress to form proper
blastocysts (Figs 1C and 2A). Whereas Plk1(+/+) embryos show
the typical Plk1 localization at the spindle poles in mitotic
metaphase cells (Fig. 2B – solid arrow heads), and also at
the mid-body and the cytokinetic furrow in anaphase cells
(Fig. 2B – thin arrows), the Plk1(/) blastocytes do not show
any positive staining for Plk1 (Fig. 2C – solid arrow heads
pointing out the spindle poles), even though they present a
high ratio of mitotic cells (42.2% in average).
A detailed immunofluorescence microscopic analysis shows
that mitotic cells in the Plk1(+/+) embryos show symmetric
bipolar spindles, with chromosomes properly arranged in the
metaphase plate (Figs. 2B and 3A). In anaphase and telophase
cells, sister chromatids seem to be equally segregated to each
daughter cell (Fig. 2B). In contrast, Plk1 null embryos displayed
a substantial arrest of cells in a prometaphase-like stage
(42.2% in average), with incomplete metaphase plates and
misaligned chromosomes (Fig. 3B). Additionally, no anaphase
and telophase figures were observed, confirming the impair-
ment of chromosome segregation. Most of the mitotic arrested
cells, in the Plk1 null embryos, displayed monopolar (34.7% in
average) or multipolar spindles (13.0% in average) with poorly
focused spindle poles (52.3% in average). Consequently, cells
also showed misaligned chromosomes (Fig. 3B – arrow heads),
thus confirming the role for Plk1 in the establishment of bipolar
spindles and proper chromosome alignment also during the
embryonic development. Interestingly, few Plk1 null cells
showed enlarged nucleus with an increased number of centro-
meres (as depicted by anti-centromere antibody (ACA) staining)
when compared with Plk1(+/+) embryos or even the neighbor-
ing cells in the same blastocyst (Fig. 3C – arrow). These cells
most likely progress through mitosis and, as a consequence
of cytokinesis defects, form polyploid cells. These cytokinesis
alterations might also explain the higher incidence of multipo-
lar spindles we observed, as polyploid cells probably enter in
the following round of division with an extra number of
centrosomes. All these cellular defects eventually can lead to
cell death, thus explaining the Plk1(/) embryo lethality by
E3.5–E5.5.
Plk1 haploinsufficient MEFs do not show any cell cycle
alteration
Because Plk1 haploinsufficient animals were born and develop
normally, we were able to obtain MEFs from Plk1(+/) E13.5
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embryos. When compared with littermates Plk1(+/+) MEFs,
Plk1(+/) expresses half the levels of Plk1 protein in both prolif-
erating and arresting cultures (Fig. 4A). Plk1(+/) cells did not
display any alteration in their cell cycle profile, showing similar
percentages within all cell cycle phases as depicted by DNA
content via flow cytometry (Fig.4B). Additionally, Plk1(+/+) and
Plk1(+/) MEFs showed similar proliferation rates (Fig. 4C). This
is consistent with the in vivo data where E16.5 heterozygous
embryos showed similar levels of BrdU incorporation rates as
their wild-type littermates (Fig. 4D). Finally, despite the reduction
on Plk1 levels in the heterozygous MEFs, these cells did
not show any significant change in ploidy when compared with
Plk1(+/+) MEFs (Fig. 4E). Altogether, these data demonstrate that
Plk1 haploinsufficiency is compatible with a normal cell cycle
progression and proliferation rate.
Conditional depletion of Plk1 leads to mitotic arrest and
cell death
In order to confirm that full depletion of Plk1 leads to mitotic arrest
and cell death, we have also generated a conditional depletion
model for Plk1, by using the CAG-Flpe transgenic strategy [55].
Two lox-P sites were inserted flanking the Plk1 exon 2 by ho-





Figure 1. Early embryonic lethality of the Polo-like kinase 1 (Plk1) null mice. A: Scheme of the Plk1 gene-trap AS0407. A splicing acceptor
sequence (SA) fused to a beta-geo (b-geo) cassette, and followed by a poly-adenilation signal (pA), are inserted into intron 2 of the Plk1murine
locus. B: Table showing the offspring Mendelian statistics of the Plk1AS0407 strain. There are no Plk1(/) born animals, neither mid-gestation
embryos (E8.5–10.5). When embryos are genotyped at E1.5 post-coitum, we find the adequate Mendelian ratio of each genotype. C: Post-
coitum embryos are extracted from crosses between Plk1(+/) animals. E1.5 embryos are cultured in vitro and followed in a daily time course
under the microscope. Whereas Plk1(+/+) and Plk1(+/) progress normally to the blastocyst stage, Plk1(/) embryos arrest at the morula
stage by E3.5 and undergo apoptosis.D: After 4 days of culture, DNA is extracted from cultured embryos and subjected to PCR using specific
oligonucleotides, in order to evaluate the insertion of the b-GEO cassette into the Plk1 locus, and determine the genotype regarding the gene
trapping. E: Plk1(+/) blastocysts express the beta-gal cassette and can be stained for beta-galactosidase in order to verify the expression of
the transgene, whereas the Plk1(+/+) that do not harbor the b-GAL cassette remain stainless.
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locus (Fig. 5A). MEFs extracted from Plk1(lox/lox) E13.5 embryos
proliferate normally, showing no differences when compared
with Plk1(+/+) control cells (data not shown). In order to deplete
Plk1 completely, Plk1(lox/lox) MEFs were synchronized by serum
starvation and infected with Adeno-CRE virus facilitating loci
excision. Plk1 depletion efficiency was verified by PCR (Fig. 5B)
and by immunoblotting (Fig. 5C).
To analyze cell cycle progression in the absence of Plk1,
Plk1(lox/lox) MEFs were synchronized in G0 by serum starva-
tion, infected with Adeno-Cre viruses and then released in
Figure 2. Mitotic arrest in the Polo-like kinase 1 (Plk1) null embryos. A: Immunoflorescence analysis of Plk1(+/+) and Plk1(/) embryos. By
E3.5., Plk1(+/+) embryos (left panel) show few mitotic cells with a normal-shaped spindle, as detected by immunostaining of α-tubulin (green)
and counterstained DNA (red). Plk1 null embryos (right panel) arrest in a 10–12 cell morula stage with most cells arrested in an aberrant mi-
tosis. Bar indicates 10 μM. B: Plk1(+/+) embryos display a precise Plk1 staining (red) at the mitotic spindles poles (arrowheads), anaphase
mid-zone and the cleavage furrow at cytokinesis (arrow). Tubulin is stained in green and DNA counterstained in blue. Bar indicates 10 μM.
C: Plk1(/) embryos do not show any Plk1 staining (red) although most of the cells are arrested in mitosis as shown by tubulin staining
(green). Arrow heads indicate the aberrant mitotic spindle poles. DNA is counterstained in blue. Bar indicates 10 μM
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high-serum media and followed in a time course (Fig. 5D).
Plk1(Δ/Δ) cells enter into the cell cycle and go through G1, S
and G2 phases with no evident restrictions (Fig. 5E). However,
36 hours post-release in high-serum media, Plk1(Δ/Δ) MEFs
showed an arrest in the mitotic phase, as measured by MPM2
staining, in contrast to Plk1(lox/lox) cells. Concomitantly, the cell
cycle DNA content profile shifts towards the G2/M peak
(Fig. 5F). Microscope examination of arrested cells revealed
all the typical mitotic aberrancies due to Plk1 inhibition, such
as monopolar and multipolar spindles, non-aligned chromo-
somes and lagging chromosomes (Fig. 5G and H).
We then wanted to extrapolate these in vitro data into the
mouse embryo, to verify that Plk1 is also essential during
post-implantation embryonic development. Plk1 is ubiquitously
expressed in the E14.5 mouse embryo as detected by immuno-
histochemical analysis (Fig. 6A). There are specific areas where
Plk1 expression is higher such as the developing neuroepithelia,
the fetal liver, intestines and other epithelial structures. Plk1 is
highly expressed in the mitotic cells along the embryo, nicely
decorating the spindle poles and the mid-body of the mitotic
cells (Fig. 6B).
To test the effects of Plk1 depletion during mid-gestation,
Plk1(+/lox) female mice were crossed with Plk1(+/lox) male
mice. At E12.5 day post-coitum, tamoxifen citrate salt (0.3mg
per gram of animal body weight) was intraperitoneally injected
into the pregnant females and the embryos were collected for
histology 2 days after tamoxifen injection, at day E14.5. Al-
though changes in the embryo size were not detected, a
detailed inspection of the proliferative areas such as the
neuroepithelia showed that Plk1 depletion impairs mitosis.
Whereas the Plk1(+/Δ) embryos displayed a normal distribu-
tion of mitotic cells in the neuroepithelia (Fig. 6C – open ar-
rows), the Plk1(Δ/Δ) embryos showed an increase in
aberrant mitotic figures, with evident alterations in chromo-
some alignment (Fig. 6C – closed arrows). There was an asso-
ciated increase in the mitotic cell population, as depicted by
A) B)
C)
Figure 3. Mitotic aberrations in the Polo-like kinase 1 (Plk1) null embryos. A: Wild type embryos contain canonical metaphases with properly
aligned chromosomes and bipolar spindles as shown by staining with α-tubulin (green), anti-centromere antibody (ACA) signal at the centromeres
(red) and counterstained DNA (blue). Bar represents 10μmdistances. B: Detailed mitotic pictures from Plk1(/) E3.5 embryos displaying severe
spindle aberrancies, with unfocused spindle poles and monopolar spindles, all accompanied with a high number of misaligned chromosomes
(open arrow heads). Bar represents 10μmdistances.C: The presence of giant cells (arrow) with decondensed chromosomes in the Plk1(/) em-
bryos suggest a defect in cytokinesis in the absence of Plk1 (right panel). These polyploid cells present around 80 ACA-stained spots (green)
whereas most the other cells in the same embryo, or in Plk1(+/+) embryos have about 40 ACA spots. Bar represents 10μm distances.
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phospho-Ser10 Histone H3 immunostaining (Fig. 6D – upper
panel). The Plk1 depletion was confirmed in the aberrant mi-
totic cells by the absence of Plk1 staining (Fig. 6D – lower
panel, closed arrows). Interestingly, similar phenotypes could
be observed in other proliferating tissues such as the fetal
liver (data not shown).
Altogether, our data confirm that Plk1 is essential during
embryonic development at several stages, and Plk1 depletion
during the mouse embryonic development leads to severe mi-
totic aberrancies such as multipolar and monopolar spindles,
lagging chromosomes and cytokinesis failures.
Discussion
From yeast to mammals, Plk1 is one of the crucial mitotic regu-
lators. In addition, Plk1 is a relevant molecule in the cancer
clinics because it is highly expressed in many tumors, it is a
poor prognostic marker and, more importantly, it is considered
as a relevant therapeutic target. There are several small-
molecule inhibitors for Plk1 already in clinical trials for cancer
therapy [50]. In this context, any relevant information of the
physiological changes generated by Plk1 inhibition in mam-




Figure 4. Polo-like kinase 1 (Plk1) haploinsuffcient mouse embryonic fibroblasts (MEFs) do not show cell cycle alterations. A: Plk1 expression anal-
ysis in MEFs from Plk1(+/) and wild-type littermates. Asynchronic (AS) or serum starved (SS) cells were subjected to immunoblot for Plk1 detection,
showing a clear reduction in Plk1 levels when comparedwith thePlk1(+/+) cells. Alpha-tubulin is used as a loading control, and Cyclin B as a read-out
of the serumstarvation. Histogram represents Plk1 protein quantification normalized versus the tubulin signal.B: DNAcontent profile, using propidium
iodide, of immortal Plk1(+/+) and Plk1(+/) MEFs showing no differences in the distribution of the different cell cycle phases. C: Proliferation curve of
MEFs derived from Plk1(+/+) and Plk1(+/) embryos. Both cell populations grow with similar kinetics. D: BrdU incorporation and quantification in
the SVZ area of brains from Plk1(+/+) and Plk1(+/) E16.5 embryos. Proliferation index in both genotypes are similar (N≥ 3 embryos per genotype).
E: Karyotyping of immortal Plk1(+/+) and Plk1(+/) MEFs showing no major differences in chromosome number.
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Figure 5. Conditional Polo-like kinase 1 (Plk1) depletion in mouse embryonic fibroblasts (MEFs) upon Cre expression. A: Scheme of the Plk1
conditional knock-out strategy. By homologous recombination, the Plk1 exon 2 is flanked with lox-P (green triangles) and Frt (orange trian-
gles) recombination sequences and a neomycin phosphotransferase cassette (NEO) generating the Plk1(frtlox) locus. Upon expression of
the Flip recombinase, the NEO cassette is excised from the Frt sites, generating the Plk1(lox) allele. Finally, when Cre recombinase is
expressed, exon 2 is removed from the Lox-P sites leading to a DNA frame shift that generates the null allele Plk1(Δ). B: Plk1 depletion val-
idation by PCR using specific oligonucleotides to detect the depleted (Δ/Δ) and the non-depleted (lox/lox) locus. C: Western blot to validate
Plk1 absence in the Plk1(Δ/Δ) cells. Nocodazole (NOC) was added to the cells during 16 hours in order to arrest cells in mitosis and detect the
maximum peak of Plk1 expression. α-tubulin is used as a loading control. D: Flow chart of the synchronization protocol for MEFs and Adeno-
Cre infection. Full confluent and serum starved Plk1(lox/lox) cells are infected with either AdCre or AdGFP viral particles during 48 hours. Then,
cells are seeded at one-sixth dilution in 10% serum media, and time points are taken each 12 hours. E: EdU incorporation FACs analysis
36 hours after entering the cell cycle. Plk1(Δ/Δ) cells are able to enter the cell cycle when recovered from the serum starvation arrest.
Plk1(Δ/Δ) cells undergo G1 and S phases with similar kinetics as the Plk1(lox/lox) control cells, as quantified in the right histogram. F: FACs
analysis 36 hours after entering into the cell cycle. Plk1(Δ/Δ) cells show an increase in the mitotic index when compared with Plk1(lox/lox)
as depicted by the staining with the mitotic marker MPM2 (upper panels) and quantification histogram. DNA content analysis, using propidium
iodide staining, shows an increase in the G2/M population of the Plk1(Δ/Δ) cells.G: Mitotic aberrancies upon Plk1 depletion. Plk1(Δ/Δ) MEFs were
subjected to immunofluorescence for alpha-tubulin (α-tub – green) and phospho-Ser10 Histone H3 (pH3 – red) and DNA counterstained with
DAPI (blue). Cells show all the classical phenotypes of Plk1 inhibition such as monopolar and multipolar spindles, and unaligned or lagging
chromosomes. H: Quantification histogram of the different mitotic fates when comparing control Plk1(lox/lox) cells versus Plk1(Δ/Δ) MEFs.
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Complete genetic depletion of Plk1 leads to embryonic lethal-
ity at the morula stage. In the present study, the Plk1(/) mor-
ula cells recapitulate all the established phenotypes associated
to Plk1 inhibition, from metaphases with misaligned chromo-
somes, tomonopolar or multipolar spindles and even cytokinesis
failure, as there are some interphase cells with double amount of
A) B)
C) D)
Figure 6. Polo-like kinase 1 (Plk1) depletion during embryonic mid-gestation leads to mitotic aberrancies. A: Plk1 expression analysis in
E16.5 mouse embryos. Plk1 is widely express in the mouse embryo as depicted by immunohistochemistry using Plk1 antibody. B: Plk1 ex-
pression is higher in the most proliferative areas such as the embryonic neuroepithelia (upper panel) and the fetal liver (lower panel). Mitotic
cells show the correct Plk1 subcellular distribution, with high staining at the spindle poles (open arrow) and the anaphase mid-zone (solid ar-
row). Bars show magnification in each microphotograph. C: Plk1 depletion leads to mitotic aberrancies in the embryonic neuroepithelia. E12.5
embryos were treated with tamoxifen, to activate Cre recombinase, and analyzed 48 hours later at day E14.5. Whereas the Plk1(+/Δ) embryos
show normal pattern of cell division at the SVZ of the brain (upper panel – open arrows), the Plk1(Δ/Δ) littermates show an increase in aberrant
mitotic figures in the brain neuroepithelia (lower panel – solid arrows). Insets show a higher magnification image of the mitotic cells. D: Immu-
nohistochemistry of phosphoSer10-Histone H3 and Plk1 in the E14.5 embryonic brains from panel C. Plk1 depletion leads to a dramatic mi-
totic arrest in the SVZ area as depicted by pSer10-H3 staining and quantification (upper panels). Concomitantly, Plk1 depletion is verified by
Plk1 staining (lower panels), where aberrant mitotic cells are devoid of Plk1 signal (solid arrows). Only a remnant of 20% of mitotic cells still
have some levels of Plk1 expression in the Plk1(Δ/Δ), whereas almost 100% of the control mitotic cells are highly stained by the Plk1 antibody
(lower panels). More than 500 cells were counted from three different embryos per genotype.
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centromeres. A previous report by J. Chen and colleagues also
showed that the constitutive genetic depletion of Plk1 leads to
embryonic lethality at the morula stage [53]. Surprisingly, these
Plk1-depleted embryos had no mitotic alterations, and cells are
somehow arrested at an interphase stage. The possible discrep-
ancies between the results observed in both reports might result
from using different gene-trap strategies. J. Chen Plk1 knock-out
mice were generated by using a gene-trap in intron 9 of the Plk1
locus. Thus, there is still the chance of having a Plk1 protein
expression in a truncated form only lacking the very C -terminal
part of the protein and, therefore, still having some functionality.
Another possible explanation for the non-mitotic phenotype is
the fact that Plk1 was also described as an important driver for
mitotic entry [56], thus, cells depleted in Plk1 would not be able
to progress through G2 and stop before reaching mitosis. Al-
though Plk1 participates in mitotic entry through phosphoryla-
tion of CDC25C, Myt1, Cyclin B and FoxM1 [57] and promotes
recovery from DNA damage [58], it is not strictly required for mi-
totic entry [20,25,41]. The most probable explanation is that
many of the proteins involved in the molecular network for mi-
totic entry are redundant in their function, as they play into sev-
eral signaling feedback loops with no exclusive dependency in
any of them. We validate that in our models all the cells are
arrested at mitosis upon Plk1 depletion, either in the mice em-
bryos or in vitro cell cultures, and there is no evidence of cell cy-
cle stoppage before mitosis. All together, these data argue
against an essential role for Plk1 in regulating mitotic entry and
confirms an essential requirement for this protein during the
formation of a functional bipolar spindle and chromosome
segregation.
The predominant phenotype described when Plk1 is
acutely chemically inhibited is the generation of monopolar
spindles due to impartment of centrosome maturation and
separation [41]. Interestingly, Plk1-depleted embryos not only
display monopolar spindles but also multipolar spindles with
unfocused poles. This circumstance probably comes from the
fact that Plk1 depletion does not happen as efficiently as the
chemical inhibition of the catalytic activity of Plk1. Thus, cells
might be able to go through mitosis with a minimal residual
of Plk1 but not have enough Plk1 levels to accomplish cytoki-
nesis properly, as this seems to be one of the more demand-
ing activities of Plk1 [24,30,59]. Consequently, cells would
exit mitosis being polyploid, and they probably enter in the
subsequent mitotic round with an extra number of centro-
somes. Another explanation is the fact that Plk1 interplays
with centrosomal proteins such as Kizuna, Aurora A or
TPX2, and this might lead to multipolar spindles as well
[60,61].
Polo-like kinase 1 null embryos are able to reach the morula
stage with 12 to 16 cells. Thus, several rounds of cell division
happened despite the Plk1 depletion. This is most probably
due to maternal contribution, because Plk1 activity inhibition
by specific drugs stops the very first mitotic division in the
mouse embryo [62]. Similarly, Plk1 is essential for the mouse
oocyte maturation, as it is critical for the oocyte meiotic re-
sumption [63].
Polo-like kinase 1 needs to be entirely depleted or acutely
inhibited in order to provoke aberrant mitosis. Meanwhile full
depletion of Plk1 leads to severe mitotic aberrancies in embryo
development and in MEFs in culture, Plk1(+/) mice are viable
and they follow the correct Mendelian ratio. In vitro, Plk1(+/)
MEFs do not show any alteration in their cell cycle profile and
have identical proliferation index as the wild-type littermates
derived cells (Fig. 4B and C). Thus, Plk1 haploinsufficiency
does neither compromise cell viability nor cell cycle progres-
sion. Concomitantly, Klaus Strebhardt and colleagues
engineered a mouse with an inducible Plk1-shRNA [54]. The
shRNA used in this report is only able to reduce Plk1 levels
up to 70% in mouse fibroblasts. These mice, even though
they are able to reduce Plk1 levels very efficiently in certain
tissues (86% in testis, 72% in bone marrow and 60% in
spleen), silencing is not complete in some others (stomach
or colon), and mice live with no major drawbacks with the
remnant Plk1. Indeed, Plk1 knocked-down animals do not dif-
fer significantly from the wild-type counter littermates in
terms of histology and metabolism. Accordingly, MEFs de-
rived from these inducible knock-down mice tolerate Plk1
reduction up to 90%, with no alteration in cell proliferation.
Plk1 being an essential kinase for cell proliferation and ani-
mal life, a minimal threshold of Plk1 expression or function
is sufficient for cell progression and thereby an interesting
observation given the current relevance of Plk1 as a putative
cancer target.
Materials and Methods
Generation of Plk1 mutant mice
We generated Plk1(+/) mutant mice by microinjection of the
ES clone AS0407 (Sanger Gene Trap Resource; http://www.
sanger.ac.uk/PostGenomics/genetrap/) into C57BL/6J blasto-
cysts. These clones carry a β-geo (fusion between neomycin-
resistant gene and β-galactosidase gene) cassette in the Plk1
intron 2 (Fig. 1A). The position of the gene-trap cassette in
these ES clones was confirmed by RT-PCR using the following
primers: IN1_F (5 -AAGGCTTCTAGCGAGGGTACTTGGCACT-3 ) and
IN1a_R (5 -GCTAGGACTAGACGCTCGGAGTGGAGA-3 ) both an-
nealing in the murine Plk1 intron 1 amplifying the wild-type al-
lele and GT6_R (5 -GGGACAGTGCAGATCCAAAA–3 ) annealing at
the β-geo cassette to detect the trapped allele.
The Plk1 conditional targeting construct was assembled fol-
lowing the same strategy as previously reported in [64]. We
flanked exon 2 of the murine Plk1 locus with loxP sequences,
thus generating the Plk1(lox) locus. A neomycin phosphotrans-
ferase (neo) cassette was used for positive selection of ES
cell clones. Recombinant ES cells and clones were selected
by southern blot. To conditionally generate a null allele Plk1(Δ),
we crossed the Plk1(+/lox) mice with transgenic mice that
express the Cre recombinase fused to the estrogen receptor
(Cre-ERT2) inserted in the collagenase locus (Fig. 5A). All
animals were maintained in a mixed 129/Sv (25%) times
CD1 (25%) times C57BL/6J (50%) background. The following
oligonucleotides for the Plk1 cKO genotyping were used:
EX1a_F (5 -ACAGCGACTTTGTATTTGTAGTTTTG-3 ) and IN1b_R (5 -
CACTTTATGAATCCATTTCCTGTACC-3 ) for detecting the wild-type
and lox alleles and IN2_R (5 -TTTCAGCTTAGTAAAGAGACA-3 ) for
the depleted allele.
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Histological and pathological analysis
Mice were housed at the pathogen-free animal facility of the
Centro Nacional de Investigaciones Oncológicas (CNIO, Madrid)
following the animal care standards of the institution. These
animals were observed on a daily basis, and sick mice were hu-
manely euthanized in accordance with the Guidelines for
Humane End Points for Animals used in biomedical research.
For histological observation, dissected organs were fixed in
10% buffered formalin (SIGMA-Aldrich St. Luis, MO, USA) and
embedded in paraffin wax. Three- or five-micrometer-thick
sections were stained with hematoxylin and eosin. Additional
immunohistochemical examination of the tissues and patholo-
gies analyzed was performed using specific antibodies against
Plk1 (rat monoclonal – laboratory made), phospho-histone H3
Ser10 (Merck-Millipore, Billerica, MA, USA. 06-570) and anti-
BrdU (GE Healthcare Buckinghamshire, UK RPN202).
Embryo cultures and immunofluorescence
Fertilized embryos were collected by flushing the uteri of preg-
nant females from crosses between Plk1(+/) mice, with
Hepes-buffered Medium 2 (M2; SIGMA-Aldrich St. Luis, MO,
USA) at E1.5-E2.5. Embryos were individually cultured in vitro in
potassium simplex optimized medium (KSOM; Chemicon Inter-
national Inc., Billerica, MA, USA) and photographed daily for up
to 5 days. For immunofluorescence analysis, embryos were fixed
with cold methanol during 1 hour at 20 °C, rinsed with M2 me-
dium, washed in phosphate buffered saline (PBS) containing
0.1% BSA (Sigma, St. Louis, MO, USA) and incubated with 0.1%
Triton X. Embryos were then blocked with 10% of serum in PBS
0.1% BSA and incubated with the following primary antibodies:
alpha-tubulin (DM1a, Sigma St. Louis, MO, USA), anti-centromere
antibody (ACA, Antibodies Inc., Davis, CA, USA), PLK1 (Abcam
ab14209, Cambridge, UK), and phospho-histone H3 Ser10 (06-
570 Merck-Millipore, Billerica, MA, USA) for 2 hours at 37 °C.
The matching secondary antibodies, with different Alexa dyes
(488, 594, 647 or 680) are from Molecular Probes (Invitrogen
Eugene, OR, USA). Images were obtained using a confocal ultra-
spectral microscope (Leica TCS-SP5-AOBS-UV, Leica-Microsystems
CMS GmbH, Mannheim, Germany).
To detect β-galactosidase activity, embryos were fixed for
5minutes in PBS containing 1% formaldehyde, 0.2% glutaral-
dehyde and 1% serum. After fixation, embryos were rinsed with
1% serum in PBS and then transferred to a β-galactosidase re-
action mixture (4mM K3Fe(CN)6, 4mM K4Fe(CN)6, 2mM MgCl2
and 1mg/ml X-gal in PBS) at 37 °C overnight. Embryos were
washed once in PBS and kept at 4 °C. Positive embryos were
scored 48 hours after the reaction was initiated.
MEFsextraction, cell cycle profile and immunofluorescence
Mouse embryonic fibroblasts were prepared from E13.5 em-
bryos and cultured using standard protocols [64]. Cell cycle
profiling analysis was performed by detecting DNA content
and EdU incorporation using the FACSCanto flow cytometry de-
vice (BD Biosciences Franklin Lakes, NJ, USA). EdU was added
to exponential growing MEFs for 20 hours, and then cells were
trypsinized and fixed in cold 70% ethanol. EdU staining protocol
was performed following manufacture instructions (Click-iT,
Invitrogen, Eugene, OR, USA), and DNA was stained with
propidium iodide for 30minutes. Mitotic index was determined
by immunostaining with anti-MPM2 antibody (Millipore 05-368).
Immunofluorescence was performed by fixing the cells in
4% paraformaldehyde in PBS. After permeabilization with cold
methanol, cells are blocked with 10% fetal bovine serum (FBS)
in PBS and probed with specific antibodies against alpha-
tubulin (DM1a, Sigma) and phospho-histone H3-Ser10 (Millipore
06-570). The secondary antibodies coupled to either Alexa488 or
Alexa594 dyes are from Molecular Probes (Invitrogen). DNA is
counterstained with DAPI, and cells are finally mounted in glass
slides using Mowiol. Pictures were obtained using a confocal
ultra-spectral microscope (Leica TCS-SP5-AOBS-UV).
Protein extraction and immunoblotting
For immunoblotting, MEFs were either asynchronous grown in
10% FBS (AS) or serum starved in 0.1% FBS for 48 hours (SS).
Cells were then lysed in RIPA lysis buffer (37mM NaCl, 0.5%
NP-40, 0.1% SDS, 1% TX-100, 20mM Tris–HCl pH 7.4, 2mM
EDTA, 10% glicerol 1mM PMSF) and supplemented with prote-
ase and phosphatase inhibitory cocktails (SIGMA-Aldrich St.
Luis, MO, USA). Proteins lysates were then separated in Criterion
XT acrylamide gels (BioRad Hercules, CA, USA), transferred to ni-
trocellulose membranes (BioRad), probed using specific primary
antibodies against PLK1 (Life Technologies 33-1700), cyclin B
(Santa Cruz Biotechnology Dallas, TX, USA. sc-594) and α-tubulin
(DM1a, Sigma) and detected using fluorescent secondary antibod-
ies coupled to Alexa680 dye (Invitrogen) using the Odyssey Infra-
red Imaging System (Li-Cor Biotechnology, Lincoln, NE, USA).
Statistical analysis
Statistical analysis was performed using Student’s t-test or anal-
ysis of variance (GraphPad Prism 5). All data are shown as mean
±SEM; probabilities of p< 0.05 were considered significant.
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